行情

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ

实时行情|Nasdaq Last Sale

9.72
+0.54
+5.88%
盘后: 9.79 +0.07 +0.72% 19:53 03/05 EST
开盘
9.34
昨收
9.18
最高
9.81
最低
8.12
成交量
152.24万
成交额
--
52周最高
25.50
52周最低
0.7010
市值
3.60亿
市盈率(TTM)
-6.0621
分时
5日
1月
3月
1年
5年
卡迪夫肿瘤学(CRDF)收到来自顶级分析师的评级更新
SmarterAnalyst · 6天前
卡迪夫肿瘤学(Cardiff Oncology)第四季每股收益($ 0.19)从去年的$(0.51)起,销售额从$ 93.00K上升为$ 119.00K
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.19) per share. This is a 62.75 percent increase over losses of $(0.51) per share from the same period last year. The company reported $119.00 thousand in
Benzinga · 02/25 22:16
卡迪夫肿瘤学宣布2020年第四季度和全年结果以及近期重点
SAN DIEGO, Feb. 25, 2021 /PRNewswire via COMTEX/ -- SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage...
PR Newswire - PRF · 02/25 21:10
10-K:CARDIFF ONCOLOGY,INC。
(EDGAR Online via COMTEX) -- ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We licensed onvansertib...
Edgar Online - (EDG = 10Q, 10K) · 02/25 21:03
卡迪夫肿瘤学将参加胃肠道(GI)肿瘤学和胰腺癌专家组在Cowen第41届年度医疗保健会议上的讨论
SAN DIEGO, Feb. 24, 2021 /PRNewswire via COMTEX/ -- SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage...
PR Newswire - PRF · 02/24 13:30
卡迪夫肿瘤学(CRDF)可能报告负收益:了解第四季度发布前的趋势
Zacks.com · 02/18 17:33
卡迪夫肿瘤学将参加LifeSci Partners精准肿瘤学日
SAN DIEGO, Feb. 16, 2021 /PRNewswire via COMTEX/ -- SAN DIEGO, Feb. 16, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage...
PR Newswire - PRF · 02/16 16:55
卡迪夫肿瘤学的Onvansertib组合与前列腺癌研究中疾病控制率的两倍提高相关
Benzinga · 02/11 16:11
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CRDF最新的财务预测,通过CRDF每股收益,每股净资产,每股现金流等数据分析Cardiff Oncology Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CRDF价格均价为26.25,最高价位30.00,最低价为23.00。
EPS
机构持股
总机构数: 120
机构持股: 2,714.82万
持股比例: 73.27%
总股本: 3,705.21万
类型机构数股数
增持
17
435.60万
建仓
55
530.08万
减持
20
125.78万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.94%
制药与医学研究
+1.63%
高管信息
Chairman/Director
Rodney Markin
Chief Executive Officer/Director
Mark Erlander
Director
Thomas Adams
Independent Director
James Armitage
Independent Director
Paul Billings
Independent Director
John Brancaccio
Independent Director
Gary Jacob
Independent Director
Gary Pace
Independent Director
Lale White
暂无数据
CRDF 简况
Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). Its programs include the development of onvansertib in a Phase-I b/2 study of onvansertib in combination with FOLFIRI/Avastin in mCRC; a Phase II study of onvansertib in combination with Zytiga (abiraterone)/prednisone in Zytiga-resistant mCRPC, and a Phase-II study of onvansertib in combination with decitabine in AML.

微牛提供Cardiff Oncology Inc(NASDAQ-CRDF)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CRDF股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CRDF股票基本功能。